← Leaderboards
Paul C Simpson
University Of California San Francisco
$6,387,489
Attributed
$7,137,416
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $860.5K · FY2005–21$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$7,137,416 · 3
VA$0 · 3
By mechanism
R01$6,137,513 · 2
RC1$999,903 · 1
I01$0 · 2
IS1$0 · 1
Top collaborators
- Anthony J. Baker2 shared
- Thomas H Everett2 shared
- Jeffrey E Olgin2 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Richard M Locksley$24,794,550
- Rosemary J Akhurst$18,718,924
- John E. Mendelson$11,971,442
- Allan Balmain$39,243,725
- Simon W. Hayward$13,277,707
Others in their field
Top investigators on “Cardiac Myocytes”
- Joseph C Wu · Stanford University$53,447,011
- Donald M Bers · Cincinnati Childrens Hosp Med Ctr$50,074,770
- Jeffery D Molkentin · Cincinnati Childrens Hosp Med Ctr$40,971,477
- Piero Anversa · New York Medical College$40,584,258
- Junichi Sadoshima · Rutgers Biomedical And Health Sciences$34,907,735
- Steven R Houser · Johns Hopkins University$33,565,081
Research focus
Cardiac MyocytesCatecholaminesMuscle CellsAdrenergic ReceptorSignal TransductionCardiacPharmaceutical PreparationsMyocardiumHeart FailureBaseBeta-Adrenergic ReceptorMouse ModelKnock-OutAgonistEpinephrineCessation Of LifeNorepinephrineStatisticsAnimalsPre-ClinicalDiagnosisReceptorAdrenergic AgonistsValidation
Grant awards (28)
An alpha-1A-adrenergic agonist drug for heart failure$383,250
R01 · FY2021 · HL · contact PI
An alpha-1A-adrenergic agonist drug for heart failure$383,250
R01 · FY2020 · HL · contact PI
Novel adrenergic mechanisms in heart failure therapy$0
I01 · FY2020 · VA · contact PI
An alpha-1A-adrenergic agonist drug for heart failure$383,250
R01 · FY2019 · HL · contact PI
ShEEP Request for Ultrasound Imaging System$0
IS1 · FY2019 · VA · contact PI
Novel adrenergic mechanisms in heart failure therapy$0
I01 · FY2019 · VA · contact PI
An alpha-1A-adrenergic agonist drug for heart failure$383,250
R01 · FY2018 · HL · contact PI
Alpha-1A-adrenergic agonist therapy for cardiomyopathy and heart failure$380,000
R01 · FY2016 · HL · contact PI
Novel therapy for cardiotoxicity of cancer drugs$0
I01 · FY2016 · VA · contact PI
Alpha-1A-adrenergic agonist therapy for cardiomyopathy and heart failure$374,300
R01 · FY2015 · HL · contact PI
Novel therapy for cardiotoxicity of cancer drugs$0
I01 · FY2015 · VA · contact PI
Alpha-1A-adrenergic agonist therapy for cardiomyopathy and heart failure$372,400
R01 · FY2014 · HL · contact PI
Novel therapy for cardiotoxicity of cancer drugs$0
I01 · FY2014 · VA · contact PI
Alpha-1A-adrenergic agonist therapy for cardiomyopathy and heart failure$380,000
R01 · FY2013 · HL · contact PI
Novel therapy for cardiotoxicity of cancer drugs$0
I01 · FY2013 · VA · contact PI
UCSF Living Heart Resource$499,903
RC1 · FY2010 · HL
Alpha-1 adrenergic receptor subtypes in cardiac growth$360,484
R01 · FY2010 · HL · contact PI
UCSF Living Heart Resource$500,000
RC1 · FY2009 · HL
Alpha-1 adrenergic receptor subtypes in cardiac growth$360,484
R01 · FY2009 · HL · contact PI
Alpha-1 adrenergic receptor subtypes in cardiac growth$360,484
R01 · FY2008 · HL · contact PI
Alpha-1 adrenergic receptor subtypes in cardiac growth$360,484
R01 · FY2007 · HL · contact PI
Alpha-1 adrenergic receptor subtypes in cardiac growth$371,250
R01 · FY2006 · HL · contact PI
Alpha-1 adrenergic receptors and cardiac growth$33,000
R01 · FY2005 · HL
Alpha-1 adrenergic receptors and cardiac growth$265,125
R01 · FY2003 · HL
Alpha-1 adrenergic receptors and cardiac growth$265,125
R01 · FY2002 · HL
Alpha-1 adrenergic receptors and cardiac growth$265,125
R01 · FY2001 · HL
MYOCARDIAL RELAXATION AND CA++ TRANSPORT IN HYPERTROPHY$231,497
R01 · FY2001 · HL
MYOCARDIAL RELAXATION AND CA++ TRANSPORT IN HYPERTROPHY$224,755
R01 · FY2000 · HL